KEDRAB® (Rabies Immune Globulin [Human]) is a biologic prepared by chromatographic fractionation from a pool of plasma collected from selected US adult human donors who have been immunized with rabies vaccine and have developed high titers of anti-rabies antibody.1

KEDRAB Is Manufactured Using 3 Specific Steps of Viral Inactivation/Removal2

Solvent/detergent treatment

Heat treatment


KEDRAB is derived from human plasma; therefore, the potential exists that KEDRAB administration may transmit infectious agents such as viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.2


KEDRAB Product Monograph

Get detailed information about the rabies virus, current post-exposure prophylaxis guidelines, and the efficacy and safety of KEDRAB for rabies exposure.


Enroll in the KEDRAB 360° Program

If you are interested in receiving the most current information about KEDRAB, proper PEP, and educational rabies resources, enroll now.

References: 1. Data on file. Kamada Ltd. 2. KEDRAB [package insert]. Fort Lee, NJ: Kedrion Biopharma Inc.; 2021.


  • Enhanced color packaging for clear identification of 2mL and 10mL dosage options
  • User-friendly vertical barcodes on vials for easier scanning

New KEDRAB packaging, with distinctive vial sizes and colors, designed to reduce chances of error

Over the next several months, you can expect to start receiving KEDRAB® (Rabies Immune Globulin [Human]) with enhanced product packaging, as pictured above. Products with new packaging will be shipped when available, and after distributors' current supplies become depleted. As such, it is likely you may not receive both the new 2mL and 10mL product packaging at the same time.